Need Help?
Copied to clipboard!

NCTN: Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer (CALGB-40603)

Study ID: CALGB-40603

NCT Number: NCT00861705

Alliance for Clinical Trials in Oncology

Submitted in collaboration with the NCTN/NCORP Data Archive

Trial Title: NCTN: Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer (CALGB-40603)

Trial Description: This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Clinical data presented in the following publication(s):

Disease type(s): Breast Neoplasm - Breast Cancer - Invasive

Clinical dataset(s) included:

Additional sequencing data are available for this trial under phs001863 and phs003801.

Additional sequencing for this trial are available in Gene Expression Omnibus under GSE154524.

You are encouraged to view the PDF data dictionaries found in the “Documents” tab of the dbGaP study page, which may contain additional information regarding the data or the associated publication(s).